Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001 -    First dose level rated as safe by independent Data Safety Monitoring Board-    Second dose level to be administered according to plan-    THE001 designed as targeted tumor treatment independent...

Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board -    Two renowned oncology experts to support the development of Thermosome's clinical candidate THE001 Munich, Germany – December 05, 2023 – Thermosome, a drug development company specializing...